Gene therapy is a promising therapeutic approach for genetic and acquired diseases
nowadays. Among DNA delivery vectors, recombinant adeno‐associated virus (rAAV) is one …

Recombinant adeno-associated virus (rAAV) is one of the prominent gene delivery vehicles
that has opened promising opportunities for novel gene therapeutic approaches. However …

Recombinant adeno‐associated virus (rAAV) vectors are a promising platform for in vivo
gene therapies. However, cost‐effective, well‐characterized processes necessary to …

In recent years, the use of adeno‐associated viruses (AAVs) as vectors for gene and cell
therapy has increased, leading to a rise in the amount of AAV vectors required during pre …

The adeno-associated virus (AAV) is one of the most potent vectors in gene therapy. The
experimental profile of this vector shows its efficiency and accepted safety, which explains its …

Due to the rise of adeno-associated viruses (AAVs) as gene therapy delivery vectors,
boundary sedimentation velocity analytical ultracentrifugation (boundary SV-AUC) has been …

The field of gene therapy has evolved and improved so that today the treatment of
thousands of genetic diseases is now possible. An integral aspect of the drug development …

The human cell line HEK293 is one of the preferred choices for manufacturing therapeutic
proteins and viral vectors for human applications. Despite its increased use, it is still …

The manufacture of viral vectors to support in vivo gene therapy is arguably the most
complex bioprocess currently in use by the biopharmaceutical industry. Recombinant …

Currently, the most common approach for manufacturing GMP-grade adeno-associated
virus (AAV) vectors involves transiently transfecting mammalian cells with three plasmids …